- Advanced search
- Immuno Portal
- Malaria Portal
Synonyms: Corlanor® | Corlentor® | Procoralan® | S-16257
ivabradine is an approved drug (EMA (2005), FDA (2015))
Compound class: Synthetic organic
Comment: Marketed drugs contain ivabradine hydrochloride (PubChem CID 3045381).
Ligand Activity Visualisation Charts
These are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts.✖
View more information in the IUPHAR Pharmacology Education Project: ivabradine
|No information available.|
|Summary of Clinical Use|
|Across Europe, ivabradine has EMA approval for the symptomatic treatment of stable angina and chronic heart failure (HF) in patients with elevated heart rates. In August 2014 the US FDA granted priority review designation for ivabradine for the treatment of chronic HF, and in April 2015 granted approval for use of the drug in cases of worsening heart failure to reduce hospitalisation.
ivabradine has been tested for heart rate-lowering efficacy in patients with postural orthostatic tachycardia syndrome (POTS) . The benefit of ivabradine over beta blockers is that it doesn't depress blood pressure, but it is not approved for treating POTS. In addition to postural orthostatic tachycardia, POTS patients also suffer from fatigue, weakness and brain fog, a set of symptoms that are experienced by 'long-COVID' patients. In view of the similar symptomology, it has been proposed that ivabradine may offer potential for managing such post-viral abnormalities in long-COVID patients.
|Mechanism Of Action and Pharmacodynamic Effects|
|Ivabradine inhibits the If current in the sinoatrial node (cardiac pacemaker) . The heart rate is slowed down without any negative effects on myocardial contractility or ventricular repolarization.|
|Clinical Trial ID||Title||Type||Source||Comment||References|
|NCT03182725||Effect of Ivabradine on Patients With Postural Orthostatic Tachycardia Syndrome||Phase 3 Interventional||University of California, San Diego|
For extended ADME data see the following:
Electronic Medicines Compendium (eMC)
European Medicines Agency (EMA)